Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis® Pan-Cancer Early Diagnostics Suite. Access the documentation here
Disclaimer: This communication and the information and documents relating to it may not be distributed, directly or indirectly, in the United States or in any other jurisdiction where such distribution is not permitted.